Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07806396 | Effect of AI-Supported Virtual Patient Chatbot Training on Nursing Students' Self-Perceived Clinical Decision-Making and Gynecological Cancer Knowledge | completed | N/A | 110 | Sakarya UniversityOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830212 | Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study | not yet recruiting | Phase 2 | 50 | Yong HeOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07837622 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 42 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00034424 | Cause of Familial Testicular Cancer | completed | — | 749 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00352924 | Agriculture Health Study | active not recruiting | — | 89,655 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00923221 | Collection of Blood From Patients With Prostate Cancer | recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02594202 | Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue | recruiting | — | 3,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03425565 | A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer(PEACOCC) | completed | Phase 2 | 48 | University College, LondonOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT04963153 | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05276973 | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | active not recruiting | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05446298 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer(PRESERVE-004) | active not recruiting | Phase 2 | 58 | OncoC4, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05588128 | Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL | recruiting | — | 350 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06202820 | CV CARE: CardioVascular Care in PC Patients | recruiting | N/A | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06703476 | A Study of Surgical Techniques During Cystectomy | recruiting | Phase 3 | 530 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06780670 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy(PSMAcTION) | recruiting | Phase 2 / Phase 3 | 443 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06855277 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC(AcTFirst) | recruiting | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC(EXACT) | recruiting | Phase 2 | 70 | Karie RuncieOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06894511 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC(PSMAndARPI) | active not recruiting | Phase 2 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07059845 | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer(FLORENZA) | recruiting | Phase 2 | 400 | AbbVieINDUSTRY | 8 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07262619 | EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | recruiting | Phase 1 / Phase 2 | 160 | Eikon TherapeuticsINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT07265739 | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer | not yet recruiting | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07620795 | Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing | not yet recruiting | N/A | 120 | Sakarya UniversityOTHER | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07824349 | JUR-003 in Adult Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Juri Biosciences, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832617 | Protoacoustic Imaging For 3D Mapping | recruiting | — | 24 | University of OklahomaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835035 | Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy | recruiting | Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02968732 | Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder | active not recruiting | N/A | 65 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03237026 | Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients | recruiting | — | 360 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03635892 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04104893 | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation(CHOMP) | active not recruiting | Phase 2 | 40 | VA Office of Research and DevelopmentFED | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04335682 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide(ARACOG) | completed | Phase 2 | 111 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04503577 | Prospective Bladder Cancer Infrastructure (ProBCI)(ProBCI) | recruiting | — | 3,600 | Prospective Bladder Cancer Infrastructure FoundationOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | active not recruiting | Phase 2 | 81 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04512209 | Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology(DCE-MRI) | completed | N/A | 22 | University Hospital, GhentOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | terminated | Phase 1 | 3 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial(PRISMA) | active not recruiting | Phase 4 | 5,000 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05920798 | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE) | active not recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06038032 | ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial(RESILIENCE) | recruiting | N/A | 148 | University of AlbertaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials